1-4 of 4
Amy J. Wagner, BA
Close
Sort by
Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD
Journal: Blood
Blood (2007) 110 (11): 3104.
https://doi.org/10.1182/blood.V110.11.3104.3104
Published: 2007
Journal Articles

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Nyla A. Heerema, PhD, John C. Byrd, MD, Leslie A. Andritsos, MD, Gerard Lozanski, MD, Kristie Blum, MD, Beth Fischer, RN, Jeffrey A. Jones, MD, Mollie E. Moran, CNP, Sarah Groering, Larry J. Schaaf, Linda S. Mahoney, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch A. Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Thomas S. Lin, MD
Journal: Blood
Blood (2007) 110 (11): 3107.
https://doi.org/10.1182/blood.V110.11.3107.3107
Published: 2007
Journal Articles

Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.

David M. Lucas, PhD, Syed-Rehan A. Hussain, PhD, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Jamie M. Allison, BA, Sara E. Guster, MS/MBA, Thomas S. Lin, MD, John C. Byrd, MD, Mark W. Julian, PhD, Elliott D. Crouser, MD, Michael R. Grever, MD
Journal: Blood
Blood (2006) 108 (11): 2098.
https://doi.org/10.1182/blood.V108.11.2098.2098
Published: 2006
Journal Articles

The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL.

Amy J. Johnson, PhD, Amy J. Wagner, BA, Lisa L. Smith, MS, David M. Lucas, PhD, Michael D. De Lay, BA, Jamie M. Allison, BA, S. Percy Ivy, MD, Thomas S. Lin, MD,PhD, John C. Byrd, MD
Journal: Blood
Blood (2006) 108 (11): 2101.
https://doi.org/10.1182/blood.V108.11.2101.2101
Published: 2006